| Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study JS Abramson, ML Palomba, LI Gordon, MA Lunning, M Wang, J Arnason, ... The Lancet 396 (10254), 839-852, 2020 | 1591 | 2020 |
| Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed … M Kamdar, SR Solomon, J Arnason, PB Johnston, B Glass, V Bachanova, ... The Lancet 399 (10343), 2294-2308, 2022 | 375 | 2022 |
| Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver R Jamwal, SM de la Monte, K Ogasawara, S Adusumalli, BB Barlock, ... Molecular pharmaceutics 15 (7), 2621-2632, 2018 | 109 | 2018 |
| Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation M Aoki, T Terada, M Kajiwara, K Ogasawara, I Ikai, O Ogawa, T Katsura, ... American Journal of Physiology-Renal Physiology 295 (1), F165-F170, 2008 | 103 | 2008 |
| Lisocabtagene Maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by … M Kamdar, SR Solomon, JE Arnason, PB Johnston, B Glass, ... Blood 138, 91, 2021 | 102 | 2021 |
| Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study JS Abramson, SR Solomon, J Arnason, PB Johnston, B Glass, ... Blood 141 (14), 1675-1684, 2023 | 99 | 2023 |
| Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors Y Fujiwara, H Nokihara, Y Yamada, N Yamamoto, K Sunami, H Utsumi, ... Cancer chemotherapy and pharmacology 76, 1143-1152, 2015 | 94 | 2015 |
| Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity M Kajiwara, T Terada, K Ogasawara, J Iwano, T Katsura, A Fukatsu, T Doi, ... Journal of human genetics 54 (1), 40-46, 2009 | 94 | 2009 |
| Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation … A Sehgal, D Hoda, PA Riedell, N Ghosh, M Hamadani, GC Hildebrandt, ... The Lancet Oncology 23 (8), 1066-1077, 2022 | 91 | 2022 |
| Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2) Haplotypes Significantly Affect the Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients K Ogasawara, SD Chitnis, RY Gohh, U Christians, F Akhlaghi Clinical pharmacokinetics 52, 751-762, 2013 | 89 | 2013 |
| Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL T Siddiqi, JD Soumerai, KA Dorritie, DM Stephens, PA Riedell, J Arnason, ... Blood, The Journal of the American Society of Hematology 139 (12), 1794-1806, 2022 | 87 | 2022 |
| Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters K Ogasawara, T Terada, T Katsura, E Hatano, I Ikai, Y Yamaoka, K Inui Drug metabolism and pharmacokinetics 25 (2), 190-199, 2010 | 82 | 2010 |
| Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in transcend NHL 001 ML Palomba, LI Gordon, T Siddiqi, JS Abramson, M Kamdar, MA Lunning, ... Blood 136, 10-11, 2020 | 78 | 2020 |
| Hepatocyte nuclear factor-4α regulates the human organic anion transporter 1 gene in the kidney K Ogasawara, T Terada, J Asaka, T Katsura, K Inui American Journal of Physiology-Renal Physiology 292 (6), F1819-F1826, 2007 | 69 | 2007 |
| Transcend CLL 004: phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia … WG Wierda, KA Dorritie, J Munoz, DM Stephens, SR Solomon, ... Blood 136, 39-40, 2020 | 65 | 2020 |
| Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer Y Fujiwara, K Tamura, S Kondo, Y Tanabe, S Iwasa, A Shimomura, ... Cancer chemotherapy and pharmacology 78, 281-288, 2016 | 62 | 2016 |
| Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney K Ogasawara, T Terada, H Motohashi, J Asaka, M Aoki, T Katsura, ... Journal of human genetics 53 (7), 607-614, 2008 | 59 | 2008 |
| Multiplex and Label-Free Relative Quantification Approach for Studying Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes Using SWATH-MS R Jamwal, BJ Barlock, S Adusumalli, K Ogasawara, BL Simons, ... Journal of Proteome Research 16 (11), 4134-4143, 2017 | 53 | 2017 |
| Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1 M Kajiwara, T Terada, J Asaka, K Ogasawara, T Katsura, O Ogawa, ... American Journal of Physiology-Renal Physiology 293 (5), F1564-F1570, 2007 | 53 | 2007 |
| Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus CG Patel, K Ogasawara, F Akhlaghi Xenobiotica 43 (3), 229-235, 2013 | 50 | 2013 |
Jeremy S. AbramsonAssociate Professor of Medicine, Harvard Medical SchoolVerified email at mgh.harvard.edu
